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We present a novel and readily accessible method facilitating cellular time-resolved 
imaging of transplanted pancreatic islets. Grafting of islets to the mouse ear pinna allows 
non-invasive, in vivo longitudinal imaging of events in the islets and enables improved 
acquisition of experimental data and use of fewer experimental animals than is possible 
using invasive techniques, as the same mouse can be assessed for the presence of 
islet infiltrating cells before and after immune intervention. We have applied this method 
to investigating therapeutic protection of beta cells through the well-established use of 
anti-CD3 injection, and have acquired unprecedented data on the nature and rapidity 
of the effect on the islet infiltrating T cells. We demonstrate that infusion of anti-CD3 
antibody leads to immediate effects on islet infiltrating T cells in islet grafts in the pinna 
of the ear, and causes them to increase their speed and displacement within 20 min of 
infusion. This technique overcomes several technical challenges associated with intra-
vital imaging of pancreatic immune responses and facilitates routine study of beta islet 
cell development, differentiation, and function in health and disease.
Keywords: type 1 diabetes, islets, multiphoton, imaging, immunotherapy, anti-cD3, T cell, autoimmunity
inTrODUcTiOn
Treatment with anti-CD3 results in reversal of established diabetes in NOD mice (1) in a TGFβ-
dependent manner (2), involving combination of early and long lasting mechanisms, including 
clearance of infiltrating cells from the islets, and a time limited reduction in the numbers of circulat-
ing T cells (3, 4). Previous work has established that anti-CD3 treatment leads to resolution of the 
lymphocytic infiltrates within 24–48 h (5), but it remains unclear whether this resolution is due 
to death of the islet-reactive cells (6) or to a change in their behavior (7–9). We have used a novel 
method for imaging infiltrating immune cells in islets transplanted into the pinna of the mouse ear 
to clarify the intra-islet events directly following anti-CD3 administration.
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Disease progression in experimental type 1 diabetes is usually 
studied by excising the pancreata from experimental mice and 
analyzing the cell content, which provides a snapshot image of 
the inflammatory status of the islets. However, this precludes an 
appreciation of the dynamic temporal nature of disease processes. 
For studying the contribution of cellular behavior in deployment 
of immune effector functions, high-resolution real-time imaging 
must be performed (10). Multiphoton laser scanning microscopy 
of isolated islets from RIP-OVA mice has been used to follow 
the behavior of inflammatory cells infiltrating the islet. This has 
revealed that stable CD8+ T  cell/APC interactions only occur 
early in islet invasion and are associated with induction of IFNγ 
production (11). Further development of intravital techniques 
confirmed this behavior in intact, in situ pancreas in the NOD 
mouse (12). However, the asynchronous infiltration of islets 
poses challenges not only for pooled islet analysis but also for 
longitudinal studies. Differences in disease progression between 
individual mice has meant that group sizes have had to be large (at 
least five mice per group) to estimate the effects of any treatment 
protocols on pancreatic events.
A way of solving the problem of continuity of observation 
while reducing the number of experimental mice is to visualize 
events in the islet through imaging, without having to remove 
the islet from the mouse (10). Although several groups have 
demonstrated feasibility of cellular imaging approaches, through 
surgical exposure of the pancreas (13) or an islet graft under the 
kidney capsule (14), the invasiveness of the procedure makes 
longitudinal studies impractical. Although technically challeng-
ing, insertion of an imaging window can allow visualization of 
islets transplanted to the kidney capsule thus facilitating repeated 
imaging over time (15). A major advance in permitting longi-
tudinal studies of islet biology has been in the imaging of islets 
transplanted into the anterior chamber of the eye (ACE) (16), 
capturing images of islet vasculature (16), insulin resistance (17), 
beta cell mass (18, 19), as well as immune cell infiltration (19, 20). 
However, while this method has clear advantages for longitudinal 
study of islet biology, relevant immunological processes may be 
strongly affected by the immune privilege given by the ACE 
environment (21–23). Anterior chamber associated immune 
deviation is believed to be caused at least in part by the high 
levels of TGF beta in the vitreous fluid (21), and this may well 
affect the immune reactions we wish to record (24–26). As our 
interest is to monitor effects of immunomodulatory treatments, 
these concerns led us to examine non-invasive imaging of islets 
in a different site, in the pinna of the ear. The mouse ear pinna is 
easily accessible by various imaging modalities and compatible 
with studies of normal immune functions. Indeed, we have pre-
viously demonstrated longitudinal in vivo imaging and normal 
immune function (antigen drainage, lymphocyte priming, and 
recirculation) of lymph nodes engrafted in the pinna (27). This 
site has also been shown to support engraftment of a variety of 
different tissues including heart, thymus, kidney, adrenal gland, 
and spleen which not only survive, but continue to function in an 
organ specific way (27–30).
To test whether islets grafted into the pinna of the ear can serve 
as an easily accessible site for non-invasive imaging of effects of 
treatments aimed to decrease islet inflammation, we determined 
that islets can indeed become established in the pinna, and that 
they continue to produce insulin and glucagon therein. We then 
investigated whether we could use intravital imaging to further 
investigate the nature of the resolution of islet immune infiltra-
tion caused by administration of non-FcR binding anti-CD3 
antibody, which is a mouse equivalent to Otelixizumab which 
has been used in clinical trials in patients (31, 32). Our data 
demonstrate that non-invasive imaging of islet grafts in the pinna 
can detect the clearance of infiltrates seen with invasive methods. 
Our results also show that in addition to any cell death occurring 
after injection of anti-CD3, there is an immediate increase in 
T cell motility after administration, indicating reduced interac-
tion with targets and APC which can have profound effects on 
T cell tolerance (33, 34).
This technique enables immunological processes to be fol-
lowed in individual animals over several time points with mini-
mal discomfort, using fewer laboratory animals and allowing for 
more accurate data acquisition.
MaTerials anD MeThODs
Mice and Diabetes Detection
NOD, NOD-scid NOD, NOD-hCD2-GFP (35), Kaede-C57BL/6 
(36) and NOD Foxp3-GFP mice (37), hCD2-GFP (38), and 
CD11cYFP (39) were bred and maintained under specific 
pathogen-free barrier conditions. C57BL/6 mice were purchased 
from Charles River. This study was carried out in accordance with 
the recommendations of the Animals (Scientific Procedures) 
Act. The protocols were approved by the UK Home Office and 
performed under the Project Licences of PG, KO, and MW. Mice 
were housed in individually ventilated cages with free access to 
standard chow and water. The facility is kept on a 12 h light, 12 h 
dark cycle. The humane endpoints for these experiments specify 
that any mouse that loses more than 15% of its body weight (com-
pared with healthy littermates), or in other ways looks unwell and 
likely to exceed the Home Office standard of moderate severity 
must be culled. However, no mice used in this study required 
early culling. At the end of the experiments, mice were culled 
using a CO2-chamber followed by dislocation of the neck. In 
cases where we were harvesting islets for transplantation it was 
important to maintain an intact bile duct, and death was instead 
confirmed through palpation of the chest to assess the absence 
of a heart beat followed by confirmation of cessation of blood 
flow. Diabetes was detected using Diastix reagent strips (Bayer 
Diagnostics, Basingstoke, UK) and confirmed by a blood glucose 
measurement of >13.3 mM, using a Breeze2 blood glucose meter 
(Bayer). All animal work was conducted under UK Home Office 
project licence regulations after approval by the Ethical Review 
Committees of the University of Cambridge and Glasgow, 
respectively.
islet isolation and Transplantation
Pancreatic islets were isolated through inflation of the pancreas 
via the bile duct (40), and islets were prepared for transplan-
tation by insertion into polyethylene tubing as previously 
described (41). Islets were prepared from mice ranging from 
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6 to 14 weeks of age, and recipient mice were between 10 and 
12 weeks of age. Analgesic (Temgesic, Reckitt Benckiser) was 
administered s.c. in the scruff prior to anesthesia (Isoflurane, 
Abbott Laboratories). Ears were immobilized using double 
sided sticky tape for creation of a pocket on the ventral side 
of the pinna using forceps. A single piece of tubing contain-
ing the islets was inserted into the pocket, and approximately 
50 islets deposited into the space. The incision was then closed 
with veterinary-grade glue (Vetbond, 3M).
aglycosyl anti-cD3 antibody
The non-Fc receptor binding anti-mouse CD3 antibody (agly 
anti-CD3) was generated through genetic engineering in the 
Waldmann Laboratory, University of Oxford as previously 
described (9). The antibody that recognizes human CD3 
(Otelixizumab) was used as a non-binding isotype control.
Multiphoton laser scanning Microscopy
Intravital microscopy studies were carried out using a Zeiss 
LSM7 MP system or a Leica SP8 MP system (Molecular 
Immunology Unit, University of Cambridge) equipped with a 
tuneable Titanium: sapphire solid-state two-photon excitation 
source (4W, Chameleon Ultra II, Coherent Laser Group) cou-
pled to an Optical Parametric Oscillator (Chameleon Compact 
OPO; Coherent). Movies were acquired for 20–30 min with an 
X–Y pixel resolution of 512 ×  512 in 2  µm Z increments. 3D 
tracking was performed using Volocity 6.1.1 (Perkin Elmer, 
Cambridge, UK) or Imaris (Bitplane). Cells were identified 
using intensity thresholding and object volume. Track plots are 
included to demonstrate the actual migration of cells relative 
to their point of origin. To calculate displacement rate, we first 
calculated the straight line distance between the point of origin 
and the point of termination of a cell track and then divided the 
distance by the duration of the cell track in minutes. Maximum 
speed is presented in micrometer per minutes. Meandering 
index (also known as confinement ratio or chemotactic index) 
is a ratio defining track straightness (ratio of displacement of 
the cell to the total length of the track) where 0 represents a 
highly confined cell that returns to its starting position, and 
1 being a cell traveling in a completely straight line. Mice were 
anaesthetized using Domitor (50 mg/kg Ketamine and 0.5 mg/kg 
Medetomidine i.p.) and placed on a heated stage. The ear of 
interest was mounted on a purpose-built stand with the use of 
veterinary-grade glue (Vetbond; 3M), enabling warming of tis-
sue throughout the experiment (maintained at 37°C). To allow 
repeated imaging sessions, veterinary glue was dissolved with 
70% ethanol, and mice given Antisedan (1 mg/kg Atipamezole 
s.c.) for reversal of the Domitor anesthesia. Blood vessels 
were visualized by i.v. injection of non-targeted quantum dots 
(Qtracker 655, Life Technologies). SYTOX was used to image 
cell death in  situ. 10  µl of 10  µM SYTOX orange (Molecular 
Probes, Thermo Fischer, UK) was injected into the ear pinna 
10  min prior to imaging to allow visualization of dead cells 
(42). To image naïve T cells in lymph nodes, DsRed expressing 
CD4+T cells from unimmunized mice were magnetically sorted 
from hCD2-DsRed animals using mouse CD4+T cell isolation 
kits (Miltenyi Biotec, Surrey, UK). 2–3 ×  106 purified T  cells 
were then adoptively transferred into naïve CD11cYFP recipient 
mice. Popliteal LNs were excised 24 h later for imaging. LNs were 
maintained by being continuously bathed in warmed (37°C), 
oxygenated CO2 independent medium (43). For studies of the 
effects of aglycosylated anti-CD3, 20  µg of active antibody or 
isotype control (9) was injected i.v. as indicated. Imaging was 
interrupted for injection of antibody, and started no more than 
5 min after injection. The results achieved in the multiphoton 
imaging facility at the University of Glasgow were also repli-
cated in the facility at the Babraham Institute, Cambridge. A 1:1 
mixture of Hypnorm (25  mg/kg) and Hypnovel (12.5  mg/kg) 
injected i.p. was used to induce anesthesia during imaging at 
the Babraham Institute. Movies were acquired for the indicated 
time with an X–Y pixel resolution of 512 ×  512 in 6.23  µm 
Z increments and a total depth of 62.3–68.53  µm with a 30  s 
frame interval.
For imaging of islets in the pancreas at the University of 
Cambridge, mice were anesthetized using 3% isoflurane, the 
pancreas externalized, submerged in surgical saline solution, and 
immobilized under a cover slip and the mouse placed in a 37°C 
environmental chamber for imaging. Islets were imaged using a 
20× water immersion objective for up to 1 h per movie. Movies 
were acquired with an X–Y pixel resolution of 512 × 512 in 2 µm 
Z increments and a total depth of 54–67 µm with a 40 s frame 
interval.
immunofluorescence
Pancreata and graft-bearing pinnae were fixed in 4% PFA 
for 72  h, dehydrated in sucrose, and mounted in OCT. 10  µm 
sections were cut on a Leica cryostat and placed on Polysine slides 
(VWR), air dried, and fixed again for 10 min in acetone. Sections 
were stained using guinea pig-anti-insulin antibody (DAKO) 
at a 1:40 dilution and detected with anti-guinea pig Alexa 546 
(Molecular Probes). Rabbit anti-human glucagon (Millipore) 
was used at a 1:50 dilution and detected with anti-rabbit Alexa 
488 (Molecular Probes). Anti-mouse CD4 (BD) was detected 
with anti-rat Alexa 488 (Molecular Probes). Nuclei were visual-
ized with DAPI (Molecular Probes). The sections were viewed 
using either a Zeiss Axioskop 2 or LSM700 Confocal (Zeiss) and 
processed using Zen software.
Flow cytometry
Cells were prepared from pancreas and islet grafts in pinna 
through manual dispersion of the tissue followed by digestion 
for 10 min at 37°C in 0.5% collagenase P solution (Sigma). Cell 
suspensions from lymph nodes were prepared through disper-
sion between glass slides. All cell preparations were resuspended 
in FACS buffer (PBS with 0.5% BSA), filtered through 30  µm 
Celltrics filters (Partec), incubated with Fc-block (eBioscience) 
and then stained with CD19 Alexa647 (eBioscience), washed, and 
resuspended in PBS containing 5% 7AAD (BD Bioscience). Data 
were collected on a Cyan Cell Cytometer (DAKO) and the data 
analyzed using FlowJo (Tree Star Inc.).
statistical analysis
Differences between two groups were assessed with a non-
parametric Mann–Whitney test, and for multiple comparisons 
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we used the non-parametric Kruskal–Wallis test with a Dunn’s 
post-test.
resUlTs
The Pinna of the ear as a site  
for islet Transplantation
To demonstrate the feasibility of the pinna as a suitable graft site 
for islets, we grafted C57BL/6 islets into the pinna of syngeneic 
C57BL/6 recipient mice. These mice have no pre-existing auto-
immunity to islets, and can accept syngeneic islet grafts under 
the kidney capsule (44). Islets of Langerhans were isolated (40) 
and prepared for transplantation as previously described (41). 
The islets were then deposited into a small pocket in the skin on 
the ventral side of the pinna (Figure  1A). Grafted islets could 
be detected in the ear pinna up to 12 weeks post-transplantation 
and were seen to produce insulin (Figure 1B) (later time points 
were not assessed). Indeed, insulin and glucagon producing cells 
were readily detected in the islets in the pinna (Figures 1C,D). 
Although the gross architecture of the islets grafted into the pinna 
appeared normal, glucagon-producing alpha cells were found 
throughout the islet rather than along the perimeter edge as seen 
in islets directly from the pancreas (Figure 1E).
To determine whether the pinna would be feasible for non-
invasive imaging, we transplanted fluorescent islets from Kaede 
C57BL/6 mice (36) into C57BL/6 recipients (Figure  1F). The 
fluorescent islets were accepted, and fluorescence could be 
detected using whole body imaging (Figure 1G) and multipho-
ton imaging (Figure 1H; Movie S1 in Supplementary Material). 
The grafted pinnae were removed after imaging and stained for 
insulin, again demonstrating the presence of insulin-producing 
cells in the grafted islets (Figures 1I–K). Thus, islets grafted to 
the ear pinna can survive, are functional, and readily amenable 
to non-invasive imaging.
Use of islet grafts in the Pinna to assess 
immune infiltration
Given that the grafted tissue can be imaged non-invasively, we 
sought to determine the potential for monitoring the T  cell 
infiltrate that mediates β cell destruction in NOD mice. We 
grafted NOD-scid islets into the pinna of CD2-GFP NOD 
recipients (Figure  2A), allowing tracking of T  cell responses 
where there is existing immune reactivity to islet antigens 
and established pancreatic immune infiltration. Ten days 
after transplantation, foci of GFP fluorescence could be 
detected, as well as individual immune cells in the infiltrate 
whose movements could be tracked (Figure  2B, top panel; 
Movie S2 in Supplementary Material). Imaging of naïve 
T cells in lymph node (Figure 2B, lower panel) demonstrates 
that the cells infiltrating the transplanted islets behave more 
like activated cells engaging a target (45), displaying a lower 
velocity and displacement than naive cells (Figure 2B, plotted 
in Figure 2C). Insulin staining of the islet graft after fixation 
of the pinna demonstrates the presence of insulin producing 
cells in the pinna, with considerable presence of infiltrating 
immune cells (Figure 2D), which corresponds to the presence 
of advanced infiltration of the islets in the pancreas of the same 
graft recipient (Figure 2E, right panel). Using an injectable cell 
death dye, Sytox, we could also monitor cell death in the grafted 
pinna while imaging (Movie S3 in Supplementary Material). 
Use of a different transgenic recipient strain in which all Foxp3 
expressing cells also express GFP, enabled imaging of the pres-
ence and behavior of Foxp3+ Treg cells in the grafts (Movie S4 
in Supplementary Material). These data demonstrate that infil-
tration of lymphocytes into the islet graft can be monitored 
and quantified in vivo without need of surgical exposure of the 
tissue for multiphoton imaging.
Determination of effects of aglycosyl 
anti-cD3 Treatment on islet grafts  
in the Pinna
To assess whether immune infiltrate into islets grafted into the 
pinna reacted in a similar way to established immunotherapy as 
infiltrates in the pancreas, we assessed the response to injection 
of a non-lytic aglycosyl anti-CD3, which can prevent rejection 
of allografts (46) and reverse overt diabetes through loss of islet 
infiltrating cells (1, 6). We grafted NOD-scid islets into the pinna 
of CD2-GFP NOD mice on day 0, and imaged infiltration on 
day 7 (Figure 3A). After an initial period of imaging (Figure 3B, 
left hand panel; Movie S5 in Supplementary Material), first 20 µg 
of isotype antibody was injected i.v. (Figure 3B, middle panel; 
Movie S6 in Supplementary Material) and then 20  µg of agly 
CD3 was injected i.v., and the same area of the graft imaged 
again to monitor any change in the behavior of infiltrating 
cells (Figure 3B, right-hand panel; Movie S7 in Supplementary 
Material). Imaging was interrupted for injection of antibody and 
started no more than 5 min after injection. Analysis of the move-
ment of the cells before and after injection of agly CD3 (Figure 3C) 
demonstrated a marked increase in speed and displacement rate 
after the injection of anti-CD3 but not isotype antibody, indicat-
ing that the active antibody had an immediate effect on the islet 
reversing the T cell arrest required for TCR binding and T cell 
activation (Figure 3D) (47). The injection of isotype antibody 
induced modest increase in cell displacement in some experi-
ments, but not to the same extent as the active anti-CD3 antibody 
(Figure 3C). The observed increase in T cell speed and displace-
ment was confirmed by identical results recorded when perform-
ing the procedure and imaging in the facilities at the University 
of Glasgow (Figure S1 and Movies S8 and S9 in Supplementary 
Material). When we injected 20 µg of agly CD3 on days 7, 8, and 9, 
and imaged again on day 10, we found that the infiltrates in the 
treated mouse, which had abundant infiltrates on day 7, were 
dispersed after 3 days of agly anti-CD3 treatment (Figure S2 in 
Supplementary Material), mirroring the effect of this treatment 
regimen in islets in the pancreas. Staining of sections of grafted 
pinnae and pancreata of islet graft recipient mice either receiv-
ing agly anti-CD3 (Figure 3E, central panels) or not (Figure 3E, 
left-hand panels), also demonstrated the reduction of infiltrating 
T cells both in islets in the pinna (Figure 3E, top panels) and 
pancreas (Figure  3E, bottom panels) after treatment. These 
results were further supported by assessment of infiltrating cells 
via flow cytometry of excised grafts from the pinna (Figure S2 in 
FigUre 1 | Pancreatic islets grafted into the pinna of the ear retain capacity to produce insulin and can be used for non-invasive imaging. (a) C57BL/6 islets were 
grafted into the pinna of syngeneic C57BL/6 recipients. (B) 12 weeks later, islets were readily detected in the pinna, and higher magnification revealed glucagon 
positive cells (green) among the insulin positive beta cells (red) (c,D). The same staining was performed on islets in the pancreas of the graft recipient (e). (F) Islets 
isolated from a Kaede transgenic mice were grafted into the pinna of syngeneic C57BL/6 mice. On day 10, the graft recipient was anaesthetized and analyzed with 
whole body imaging and multiphoton microscopy. (g) On day 10, green fluorescent islets could be detected in the pinna using whole body imaging. An arrow 
indicates the fluorescent mass in the grafted ear. (h) The green fluorescent grafted islets could also be detected with multiphoton imaging (3D rendering of a  
Z-stack capture). (i,J) The graft bearing pinnae were fixed and stained to check for insulin production (red), and compared with a cross section of a control  
pinna (K). The selected images are representative of results from groups containing at least three mice.
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Supplementary Material), showing a decrease in the presence 
of GFP positive T cells in mice treated with agly anti-CD3 com-
pared with isotype antibody treated controls. We confirmed that 
the observed change in behavior in the islet infiltrating cells in 
the pinna is representative of the events in the native pancreas 
after injection of agly anti-CD3 by direct imaging of the pan-
creas. We found that islet infiltrating T cells increase their speed 
and displacement after injection of agly anti-CD3 antibody in a 
similar way as the infiltrates in the pinna islet grafts (Figure 4; 
Movies S10 and S11 in Supplementary Material).
FigUre 2 | Imaging of T cell infiltration in NOD-scid islets transplanted into the pinna of the ear of a CD2-GFP NOD recipient. (a) On day 0, islets were isolated from 
a NOD-scid mouse and grafted into the pinna of a CD2-GFP NOD mouse. On day 10, the graft recipient was anesthetized and the graft imaged using multiphoton 
microscopy. (B) Multiphoton imaging showing either islet-infiltrating GFP+ T cells (green) around a grafted islet in a 12-week old NOD recipient intact ear pinna (top 
panels), or naïve T cells moving in a lymph node (bottom panels). Scale bars represent 100 µm. The right-hand side flower plots demonstrate the movement of the 
T cells during imaging (B), presented in graph form in (c). After imaging, the pinna (D) and pancreas (e) were fixed and stained for insulin (red) and DNA stain DAPI 
(blue). T cells can be identified by green GFP signal. The selected images are representative of results from groups containing ≥ three mice.
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DiscUssiOn
By engrafting islets to the ear pinna, we have circumvented issues 
of immune privilege and invasiveness to allow study of immune 
mechanisms mediating beta cell destruction and therapeutic 
efficacy. It has been shown that the pinna of the ear is a suit-
able site for transplantation of a range of tissues (28–30) and for 
multiphoton imaging (27), supporting conventional lymphatic 
drainage, revascularization of the grafted tissue, and normal lym-
phocyte responses (27, 28). Furthermore, the pinna represents 
an easily accessible tissue for the grafting procedure as well as 
for microscope access and minimization of drift during imaging, 
making this an ideal site for longitudinal in vivo cellular imaging 
studies. We show that anti-CD3 treatment leads to an immediate 
increase in movement and displacement of infiltrating immune 
cells in islets in the pancreas, and that we can use imaging of islets 
transplanted into the pinna to image this process in a less invasive 
way. We present unprecedented data on the nature and rapidity of 
the effect on the islet infiltrating T cells.
In the more than 20  years since Lucienne Chatenoud’s 
pioneering experiments demonstrating reversal of diabetes in 
experimental mice (1), the mechanisms through which the anti-
CD3 antibodies exert their effect have been gradually clarified. 
They work through a wide array immediate and long-term effects, 
including downregulation of the CD3 signaling complex (48), 
induction of anergy and apoptosis (49, 50), and increased regula-
tion through elevated levels of TGF beta (24) and an expanded Treg 
pool (6, 51), as reviewed in Ref. (3, 4). A compelling suggestion 
is that the observed increase in the Foxp3+ Treg population after 
anti-CD3 treatment is due to a preferential depletion of activated 
T cells (6), a theory which has been supported by studies using 
OVA specific cells (6, 46). Our studies utilizing GFP labeled islet 
antigen-specific Th1 cells for tracking cell fate, while replicating 
the finding of a retained Treg pool, did not, in this model, find a 
preferential depletion of islet-specific effector T cells by anti-CD3 
treatment (9). Instead we found an induction of anergy accompa-
nied by an increase in PD-1 expression in this cell subset, which 
prevented further activation of islet antigen-presenting APC. 
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FigUre 3 | Continued
FigUre 4 | Imaging of T cell infiltration in a pancreatic CD2-GFP NOD islet before and after administration of agly anti-CD3. (a) The mouse was anesthetised, the 
pancreas externalized, and mounted for multiphoton microscopy imaging. The infiltrated islet was imaged before and after i.v. administration of 20 µg of agly 
anti-CD3. Still image from acquired Z-stack longitudinal multiphoton imaging showing islet-infiltrating GFP+ T cells (green) moving around an islet in a 12-week old 
NOD recipient before injection [(a), left panel], and after injection of aglycosyl anti-CD3 [(a), right panel]. The white bar represents 50 µm. Red = blood vessels, 
blue = collagen (secondary harmonic signal), green = GFP. (B) Depiction of the individual tracks of infiltrating cells during the imaging period (59 min and 20 s)  
in the indicated conditions. Data were only acquired from the top part of the capture, as the infiltrates in the lower parts were too dense to track. (c) Plotting of  
the recorded displacement (left) and speed (right) of islet infiltrating cells before and after administration of aglycosyl anti-CD3. The difference between groups  
was assessed using a non-parametric Mann–Whitney test, and the data are representative of three independent experiments.
FigUre 3 | Imaging of T cell infiltration in NOD-scid islets transplanted into the pinna of the ear of a CD2-GFP NOD recipient before and after administration of agly 
anti-CD3. (a) On day 0, islets were isolated from a NOD-scid mouse and grafted into the pinna of a CD2-GFP NOD mouse. On day 7, the graft recipient was 
anesthetized and the graft imaged using multiphoton microscopy. Then 20 µg of first isotype control antibody and then agly anti-CD3 was administered i.v. and the 
graft imaged again. (B) Still images from acquired Z-stack longitudinal multiphoton imaging showing islet-infiltrating GFP+ T cells (green) moving around a grafted 
islet in a 12-week-old NOD recipient before injection [(B), left panel], after injection of isotype control antibody [(B), center panel], and after injection of aglycosyl 
anti-CD3 [(B), right panel]. The white bar represents 50 µm. Red = blood vessels, blue = collagen (secondary harmonic signal), green = GFP. (c) Depiction of the 
individual tracks of infiltrating cells during the imaging period in the indicated conditions. (D) Plotting of the recorded displacement rate (left) and max speed (right) of 
islet infiltrating cells before and after administration of isotype antibody or aglycosyl anti-CD3. The data are representative of five independent experiments and 
differences between groups were analyzed using a non-parametric Kruskal–Wallis test with a Dunn’s post-test for multiple comparisons. (e) Section staining of 
pinnae [(e), top panels] and pancreas [(e), bottom panels] from isotype control injected graft recipients [(e), left-hand panels] and aglycosyl anti-CD3 injected  
[(e), middle panels] or control pinna (top right panel). Red = insulin, blue = DAPI, green = GFP.
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Induced anergy in effector T cells is often referred to as exhaus-
tion (52) as it shares many of the same markers, importantly high 
expression of PD-1. There is an accumulation of CD8+ T cells with 
an exhausted phenotype in type 1 diabetes patients that respond 
well to Teplizumab treatment (as measured through preservation 
of c-peptide production) (53, 54). Studies in islet allograft models 
also indicate induction of anergy and upregulation of PD-1 on 
both graft infiltrating CD8+ T  cells (55) and CD4+ T  cells (8) 
after anti-CD3 treatment, suggesting that induction of anergy in 
the effector population rather than expansion of the Treg pool 
is what affords long-term tolerance after anti-CD3 treatment 
(8). The requirement for effects on already primed cells is also 
supported by studies of the importance of timing of the treat-
ment. Anti-CD3 treatment is only effective if administered once 
the mice have become diabetic, and not before (5). The effects 
of anti-CD3 treatment on tolerance to transplanted tissue is also 
highly dependent on the timing of administration (46, 56), with 
treatment coinciding with the priming of allo-reactive immune 
responses (3–7  days after transplant) affording long-term graft 
survival due to preferential activation of tolerogenic pathways (7).
It is well established that recently diagnosed diabetic NOD mice 
revert to euglycemia within 24–48 h after anti-CD3 treatment (5). 
We have used non-invasive imaging of islets transplanted into the 
pinna of the ear to assess just how quickly the effects of the anti-
CD3 treatment can be observed. Autoimmune infiltration of islets 
grafted to the ear pinna is readily imaged directly through the skin 
allowing both dynamic and longitudinal imaging of lymphocyte 
responses. We observed that the T cells infiltrating the transplanted 
islets were less mobile than those swarming around in a naïve 
lymph node, most likely indicating that they had received activa-
tion through the TCR and were engaged with a target (57). This 
mirrors the behavior observed in tumor infiltrating T cells, which 
arrest on tumor cells expressing their cognate antigen (58, 59), 
the antigen-induced migration arrest of T  cells infiltrating a 
mis-matched skin graft (60) and mycobacteria-specific T cells in 
a cognate antigen rich environment (61). When we administered 
the non-FcR binding anti-CD3 antibody, we saw a rapid increase 
in the mobility of the infiltrating T cells in the islets, more similar 
to the swarming behavior of T cells which have not yet found a 
suitable APC. A cessation of the TCR-MHC interaction, be it either 
CTL attacking a beta cell or a CD4+ T  cell receiving activating 
signals from an intra-islet APC, will naturally have dampening 
effects on the ongoing inflammation. As CTL function as “serial 
killers,” moving from one target to the next (62), an interruption 
of the progress of just one cell can save several potential targets. 
Interaction time is also of crucial importance for acquisition of 
effector properties (43), and decreased interaction time between 
APC and T  cell contributes to the tolerization of both CD8+ 
T cells (33) and CD4+ T cells (34), reducing their production of 
proinflammatory cytokines and expression of surface activa-
tion markers. The long-lasting effects of short-term anti-CD3 
treatment involve the interruption and qualitative change of the 
anti-islet immune response, and non-specific bystander T cells are 
cleared from the islet just as the islet-specific effectors are. This 
indicates that anti-CD3 treatment affects not only the T cells, but 
by extension also the pro-inflammatory milieu in the islet, possibly 
via effects on antigen-presenting cells (9), breaking the cascade of 
proinflammatory events that would otherwise result in diabetes. 
Thus, the observed increase in motility may well influence both the 
short-term and long-term effects of anti-CD3 treatment, i.e., the 
cessation of interaction and downregulation of CD3, but also a 
skewing of the ensuing immune response to be more tolerogenic. 
In relation to the demonstrated need for TGFβ, we surmise that the 
consequent clearance of residual apoptotic cells during the resolu-
tion phase of healing may trigger release of active TGF-β, modifying 
the local microenvironment to acquire a level of immune privilege 
(63). In summary, imaging revealed a hitherto undescribed rapid-
ity in response to treatment, with graft infiltrating cells recovering 
motility and thus terminating the cell–cell inte ractions required 
for T cell activation (47) within 20 min of injection of the aglycosyl 
anti-CD3 antibody. Repeated imaging of the same animal revealed 
the eventual loss of infiltrating T cells at the graft site.
Importantly, this technique offers an opportunity for reduc-
tion of the number of experimental animals used in research, as 
the non-invasive nature of the investigation allows longitudinal 
monitoring of the same islets in the same host. In addition, cur-
rent models employing grafting of islets require a high degree 
of surgical proficiency while insertion into the ear pinna is 
minimally invasive. Traditional use of large groups of mice for 
temporal studies introduces experimental variation due to differ-
ing levels of immune infiltration in the pancreatic islet. The ability 
to collect data at several time points in the same experimental 
mouse negates this variance and enhances data quality. The 
amenable nature of beta islet grafting to the ear pinna makes this 
technique a new tool for studies of immune response in diabetes. 
The development of functional probes and new analytical tools is 
increasing the options for investigating immune responses in vivo 
with multiphoton imaging, and offers exciting opportunities for 
studies of type 1 diabetes. Combined use of IFN-γ reporter mice 
and Foxp3 reporter mice could clarify any differences in behavior 
of different cell subsets in the islets in response to treatment, and 
recent advances may soon allow studies of molecular dynamics 
in individual islet infiltrating cells (64). We have used islets trans-
planted into the pinna to clarify the events immediately following 
anti-CD3 treatment, and we now look forward to investigating 
the parameters required for establishment and maintenance of 
long-term tolerance. The use of the pinna as a site for islet trans-
plantation could also facilitate studies of changes in islet mass 
over time and beta cell physiology (65, 66), and we hope that a 
combination of advances in both beta cell and immune cell imag-
ing will lead to new insights into the biology of type 1 diabetes and 
thus, opportunities for treatment.
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MOvie s1 | Kaede-C57BL/6 fluorescent islets transplanted into the pinna 
of the ear of a wt C57BL/6 mouse. Image capture starts at the bottom of 
the Z stack (middle of the ear) and moves to the top (up through the dermis 
to the epidermis). The movie shows the Kaede transplanted islets in green, 
vasculature in red (Qdot tracer given i.v. prior to imaging), and the blue is 
second harmonic autofluorescence generated by the dermal collagen fibers. 
Each stack is roughly 150 µm thick. Loops of blood vessels going around 
hair follicles (which are the round holes in the collagen network) show  
up in red.
MOvie s2 | 16-min capture of pinna with NOD scid islets transplanted into 
a NOD-hCD2-GFP recipient. T cells are green (GFP), blood vessels are red 
(Q-dots), and collagen is blue (secondary harmonic signal).
MOvie s3 | 24-min capture of pinna with NOD scid islets transplanted into 
a NOD-hCD2-GFP recipient. T cells are green (GFP), blood vessels are white 
(Q-dots), and collagen is blue (secondary harmonic signal), while dead cells 
become red through uptake of Sytox dye.
MOvie s4 | 13-min capture of pinna with NOD scid islets transplanted into a 
NOD-Foxp3-GFP recipient. Foxp3+ T cells are green (GFP), blood vessels are 
red (Q-dots), and collagen is blue (secondary harmonic signal).
MOvie s5 | 15-min capture of pinna with NOD scid islets transplanted into a 
NOD-hCD2-GFP recipient (depicted in Figure S1 in Supplementary Material) 
before injection of antibody. T cells are green (GFP), blood vessels are red 
(Q-dots), and collagen is blue (secondary harmonic signal).
MOvie s6 | 15-min capture of pinna with NOD scid islets transplanted into a 
NOD-hCD2-GFP recipient (depicted in Figure S1 in Supplementary Material) after 
injection of isotype control antibody. T cells are green (GFP), blood vessels are 
red (Q-dots), and collagen is blue (secondary harmonic signal).
MOvie s7 | 29-min capture of pinna with NOD scid islets transplanted into a 
NOD-hCD2-GFP recipient (depicted in Figure S1 in Supplementary Material) after 
injection of agly anti-CD3 antibody. T cells are green (GFP), blood vessels are red 
(Q-dots), and collagen is blue (secondary harmonic signal).
MOvie s8 | 29-min capture of pinna with NOD scid islets transplanted into a 
NOD-hCD2-GFP recipient before injection of agly anti-CD3 antibody. T cells are 
green (GFP), blood vessels are red (Q-dots), and collagen is blue (secondary 
harmonic signal).
MOvie s9 | 32-min capture of pinna with NOD scid islets transplanted into a 
NOD-hCD2-GFP recipient after injection of agly anti-CD3 antibody. T cells are 
green (GFP), blood vessels are red (Q-dots), and collagen is blue (secondary 
harmonic signal).
MOvie s10 | 59-min capture of a pancreatic islet with immune cell infiltrate in 
a NOD-hCD2-GFP mouse before injection of antibody. T cells are green (GFP), 
blood vessels are red (Q-dots), and collagen is blue (secondary harmonic signal).
MOvie s11 | 59-min capture of a pancreatic islet with immune cell infiltrate in 
a NOD-hCD2-GFP mouse after injection of agly anti-CD3 antibody. T cells are 
green (GFP), blood vessels are red (Q-dots), and collagen is blue (secondary 
harmonic signal).
reFerences
1. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-
term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl 
Acad Sci U S A (1994) 91(1):123–7. doi:10.1073/pnas.91.1.123 
2. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-
beta-dependent mechanisms mediate restoration of self-tolerance induced by 
antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 9(9):1202–8. 
doi:10.1038/nm924 
3. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treat-
ment of autoimmunity. Nat Rev Immunol (2007) 7(8):622–32. doi:10.1038/ 
nri2134 
4. Kuhn C, Besancon A, Lemoine S, You S, Marquet C, Candon S, et  al. 
Regulatory mechanisms of immune tolerance in type 1 diabetes and their 
failures. J Autoimmun (2016) 71:69–77. doi:10.1016/j.jaut.2016.05.002 
5. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self toler-
ance in overtly diabetic NOD mice. J Immunol (1997) 158(6):2947–54. 
6. Penaranda C, Tang Q, Bluestone JA. Anti-CD3 therapy promotes tolerance 
by selectively depleting pathogenic cells while preserving regulatory T cells. 
J Immunol (2011) 187(4):2015–22. doi:10.4049/jimmunol.1100713 
7. Baas MC, Besancon A, Sawitzki B, Mangez C, Valette F, Chatenoud L, et al. 
Intragraft mechanisms associated with the immunosuppressive versus the 
tolerogenic effect of CD3 antibodies in a mouse model of islet  allografts. 
Transplant Proc (2013) 45(5):1895–8. doi:10.1016/j.transproceed.2013.01.054 
8. Besancon A, Baas M, Goncalves T, Valette F, Waldmann H, Chatenoud L, et al. 
The induction and maintenance of transplant tolerance engages both regu-
latory and anergic CD4+ T cells. Front Immunol (2017) 8:218. doi:10.3389/
fimmu.2017.00218 
9. Wallberg M, Recino A, Phillips J, Howie D, Vienne M, Paluch C, et  al. 
Anti-CD3 treatment up-regulates programmed cell death protein-1 expres-
sion on activated effector T  cells and severely impairs their inflammatory 
capacity. Immunology (2017) 151(2):248–60. doi:10.1111/imm.12729 
10. Benson RA, Brewer JM, Garside P. Visualizing and tracking T cell motility 
in vivo. Methods Mol Biol (2017) 1591:27–41. doi:10.1007/978-1-4939-6931-9_3 
11. Friedman RS, Lindsay RS, Lilly JK, Nguyen V, Sorensen CM, Jacobelli J, 
et  al. An evolving autoimmune microenvironment regulates the quality of 
effector T cell restimulation and function. Proc Natl Acad Sci U S A (2014) 
111(25):9223–8. doi:10.1073/pnas.1322193111 
12. Lindsay RS, Corbin K, Mahne A, Levitt BE, Gebert MJ, Wigton EJ, et al. 
Antigen recognition in the islets changes with progression of autoimmune 
11
Benson et al. Imaging of Anti-CD3-Mediated Effects in T1D
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1006
islet infiltration. J Immunol (2015) 194(2):522–30. doi:10.4049/jimmunol. 
1400626 
13. Coppieters K, Martinic MM, Kiosses WB, Amirian N, von Herrath M. A novel 
technique for the in vivo imaging of autoimmune diabetes development in 
the pancreas by two-photon microscopy. PLoS One (2010) 5(12):e15732. 
doi:10.1371/journal.pone.0015732 
14. Nyqvist D, Mattsson G, Kohler M, Lev-Ram V, Andersson A, Carlsson P-O, 
et al. Pancreatic islet function in a transgenic mouse expressing fluorescent 
protein. J Endocrinol (2005) 186(2):333–41. doi:10.1677/joe.1.06204 
15. Bertera S, Geng X, Tawadrous Z, Bottino R, Balamurugan AN, Rudert WA, 
et  al. Body window-enabled in  vivo multicolor imaging of transplanted 
mouse islets expressing an insulin-timer fusion protein. Biotechniques (2003) 
35(4):718–22. 
16. Speier S, Nyqvist D, Kohler M, Caicedo A, Leibiger IB, Berggren P-O. 
Noninvasive high-resolution in vivo imaging of cell biology in the anterior 
chamber of the mouse eye. Nat Protoc (2008) 3(8):1278–86. doi:10.1038/
nprot.2008.118 
17. Paschen M, Moede T, Leibiger B, Jacob S, Bryzgalova G, Leibiger IB, et al. Non-
invasive cell type selective in vivo monitoring of insulin resistance dynamics. 
Sci Rep (2016) 6:21448. doi:10.1038/srep21448 
18. Chmelova H, Cohrs CM, Chouinard JA, Petzold C, Kuhn M, Chen C, et al. 
Distinct roles of beta-cell mass and function during type 1 diabetes onset and 
remission. Diabetes (2015) 64(6):2148–60. doi:10.2337/db14-1055 
19. Berclaz C, Schmidt-Christensen A, Szlag D, Extermann J, Hansen L, Bouwens A, 
et al. Longitudinal three-dimensional visualisation of autoimmune diabetes 
by functional optical coherence imaging. Diabetologia (2016) 59(3):550–9. 
doi:10.1007/s00125-015-3819-x 
20. Schmidt-Christensen A, Hansen L, Ilegems E, Fransen-Pettersson N, Dahl U, 
Gupta S, et  al. Imaging dynamics of CD11c(+) cells and Foxp3(+) cells in 
progressive autoimmune insulitis in the NOD mouse model of type 1 diabetes. 
Diabetologia (2013) 56(12):2669–78. doi:10.1007/s00125-013-3024-8 
21. Streilein JW. Anterior chamber associated immune deviation: the 
privilege of immunity in the eye. Surv Ophthalmol (1990) 35(1):67–73. 
doi:10.1016/0039-6257(90)90048-Z 
22. Bhowmick S, Clark RB, Brocke S, Cone RE. Antigen-specific splenic CD4+ 
and CD8+ regulatory T  cells generated via the eye, suppress experimental 
autoimmune encephalomyelitis either at the priming or at the effector phase. 
Int Immunol (2011) 23(2):119–28. doi:10.1093/intimm/dxq461 
23. Niederkorn JY. Corneal transplantation and immune privilege. Int Rev 
Immunol (2013) 32(1):57–67. doi:10.3109/08830185.2012.737877 
24. Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3-specific 
antibody-induced immune tolerance involves transforming growth factor-beta 
from phagocytes digesting apoptotic T cells. Nat Med (2008) 14(5):528–35. 
doi:10.1038/nm1749 
25. Wallberg M, Wong FS, Green EA. An islet-specific pulse of TGF-beta abro-
gates CTL function and promotes beta cell survival independent of Foxp3+ 
T cells. J Immunol (2011) 186(4):2543–51. doi:10.4049/jimmunol.1002098 
26. Thomas DC, Wong FS, Zaccone P, Green EA, Wallberg M. Protection of islet 
grafts through transforming growth factor-beta-induced tolerogenic dendritic 
cells. Diabetes (2013) 62(9):3132–42. doi:10.2337/db12-1740 
27. Gibson VB, Benson RA, Bryson KJ, McInnes IB, Rush CM, Grassia G, et al. 
A novel method to allow noninvasive, longitudinal imaging of the murine 
immune system in  vivo. Blood (2012) 119(11):2545–51. doi:10.1182/
blood-2011-09-378356 
28. Cardillo F, Mengel J, Garcia SB, Cunha FQ. Mouse ear spleen grafts: a model 
for intrasplenic immunization with minute amounts of antigen. J Immunol 
Methods (1995) 188(1):43–9. doi:10.1016/0022-1759(95)00200-6 
29. Hillebrands JL, Klatter FA, Raue HP, Koops RA, Hylkema MN, Rozing J. An 
alternative model to study intrathymic tolerance induction: the neonatal heart-
in-ear transplantation model in the rat. Transplant Proc (1999) 31(3):1563–6. 
doi:10.1016/S0041-1345(99)00038-X 
30. Chen BJ, Jiao Y, Zhang P, Sun AY, Pitt GS, Deoliveira D, et  al. Long-term 
in vivo imaging of multiple organs at the single cell level. PLoS One (2013) 
8(1):e52087. doi:10.1371/journal.pone.0052087 
31. Ambery P, Donner TW, Biswas N, Donaldson J, Parkin J, Dayan CM. Efficacy 
and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in 
preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, 
a randomized, placebo-controlled, double-blind, multi-centre study. Diabet 
Med (2014) 31(4):399–402. doi:10.1111/dme.12361 
32. Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, 
et  al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 
study: results of the randomized phase III study in recent-onset human type 1 
diabetes. Diabetes Care (2014) 37(10):2746–54. doi:10.2337/dc13-0327 
33. Hugues S, Fetler L, Bonifaz L, Helft J, Amblard F, Amigorena S. Distinct T cell 
dynamics in lymph nodes during the induction of tolerance and immunity. 
Nat Immunol (2004) 5(12):1235–42. doi:10.1038/ni1134 
34. Katzman SD, O’Gorman WE, Villarino AV, Gallo E, Friedman RS, Krummel MF, 
et al. Duration of antigen receptor signaling determines T-cell tolerance or 
activation. Proc Natl Acad Sci U S A (2010) 107(42):18085–90. doi:10.1073/
pnas.1010560107 
35. Raine T, Zaccone P, Mastroeni P, Cooke A. Salmonella typhimurium infection 
in nonobese diabetic mice generates immunomodulatory dendritic cells able 
to prevent type 1 diabetes. J Immunol (2006) 177(4):2224–33. doi:10.4049/
jimmunol.177.4.2224 
36. Tomura M, Yoshida N, Tanaka J, Karasawa S, Miwa Y, Miyawaki A, et  al. 
Monitoring cellular movement in  vivo with photoconvertible fluorescence 
protein “Kaede” transgenic mice. Proc Natl Acad Sci U S A (2008) 105(31): 
10871–6. doi:10.1073/pnas.0802278105 
37. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal 
developmental pathways for the generation of pathogenic effector TH17 and 
regulatory T cells. Nature (2006) 441(7090):235–8. doi:10.1038/nature04753 
38. de Boer J, Williams A, Skavdis G, Harker N, Coles M, Tolaini M, et  al. 
Transgenic mice with hematopoietic and lymphoid specific expression of Cre. 
Eur J Immunol (2003) 33(2):314–25. doi:10.1002/immu.200310005 
39. Lindquist RL, Shakhar G, Dudziak D, Wardemann H, Eisenreich T, Dustin ML, 
et  al. Visualizing dendritic cell networks in  vivo. Nat Immunol (2004) 
5(12):1243–50. doi:10.1038/ni1139 
40. Szot GL, Koudria P, Bluestone JA. Murine pancreatic islet isolation. J Vis Exp 
(2007) 7:255. doi:10.3791/255 
41. Szot GL, Koudria P, Bluestone JA. Transplantation of pancreatic islets into 
the kidney capsule of diabetic mice. J Vis Exp (2007) 9:404. doi:10.3791/404 
42. Stephen J, Scales HE, Benson RA, Erben D, Garside P, Brewer JM. Neutrophil 
swarming and extracellular trap formation play a significant role in alum 
adjuvant activity. NPJ Vaccines (2017) 2:1. doi:10.1038/s41541-016-0001-5 
43. Benson RA, MacLeod MK, Hale BG, Patakas A, Garside P, Brewer JM. Antigen 
presentation kinetics control T cell/dendritic cell interactions and follicular 
helper T cell generation in vivo. Elife (2015) 4:1–16. doi:10.7554/eLife.06994 
44. Korsgren O, Jansson L. Characterization of mixed syngeneic-allogeneic and 
syngeneic-xenogeneic islet-graft rejections in mice. Evidence of functional 
impairment of the remaining syngeneic islets in xenograft rejections. J Clin 
Invest (1994) 93(3):1113–9. doi:10.1172/JCI117063 
45. Cockburn IA, Amino R, Kelemen RK, Kuo SC, Tse SW, Radtke A, et al. In vivo 
imaging of CD8+ T  cell-mediated elimination of malaria liver stages. Proc 
Natl Acad Sci U S A (2013) 110(22):9090–5. doi:10.1073/pnas.1303858110 
46. You S, Zuber J, Kuhn C, Baas M, Valette F, Sauvaget V, et  al. Induction of 
allograft tolerance by monoclonal CD3 antibodies: a matter of timing. Am 
J Transplant (2012) 12(11):2909–19. doi:10.1111/j.1600-6143.2012.04213.x 
47. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. Interactions between 
PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. 
Nat Immunol (2009) 10(11):1185–92. doi:10.1038/ni.1790 
48. Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, et  al. 
Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation 
to serum levels of tumor necrosis factor and interferon-gamma [corrected]. 
N Engl J Med (1989) 320(21):1420–1. doi:10.1056/NEJM198905253202117 
49. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 
monoclonal antibodies deliver a partial T  cell receptor signal and induce 
clonal anergy. J Exp Med (1997) 185(8):1413–22. doi:10.1084/jem.185.8.1413 
50. Smith JA, Tang Q, Bluestone JA. Partial TCR signals delivered by FcR-
nonbinding anti-CD3 monoclonal antibodies differentially regulate individual 
Th subsets. J Immunol (1998) 160(10):4841–9. 
51. Mehta DS, Christmas RA, Waldmann H, Rosenzweig M. Partial and 
transient modulation of the CD3-T-cell receptor complex, elicited by 
low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease 
remission in non-obese diabetic mice. Immunology (2009) 130(1):103–13. 
doi:10.1111/j.1365-2567.2009.03217.x 
52. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senes-
cence, and stemness in the tumor microenvironment. Curr Opin Immunol 
(2013) 25(2):214–21. doi:10.1016/j.coi.2012.12.003 
12
Benson et al. Imaging of Anti-CD3-Mediated Effects in T1D
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1006
53. Long SA, Thorpe J, DeBerg HA, Gersuk V, Eddy J, Harris KM, et al. Partial 
exhaustion of CD8 T cells and clinical response to teplizumab in new-onset 
type 1 diabetes. Sci Immunol (2016) 1(5):eaai7793. doi:10.1126/sciimmunol.
aai7793 
54. Long SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, et al. Remodeling 
T  cell compartments during anti-CD3 immunotherapy of type 1 diabetes. 
Cell Immunol (2017) 319:3–9. doi:10.1016/j.cellimm.2017.07.007 
55. Baas M, Besancon A, Goncalves T, Valette F, Yagita H, Sawitzki B, et  al. 
TGFbeta-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell 
anergy in transplant tolerance. Elife (2016) 5:e08133. doi:10.7554/eLife. 
08133 
56. Calderon D, Prot M, You S, Marquet C, Bellamy V, Bruneval P, et al. Control 
of immune response to allogeneic embryonic stem cells by CD3 antibody- 
mediated operational tolerance induction. Am J Transplant (2016) 16(2): 
454–67. doi:10.1111/ajt.13477 
57. Mueller SN. Effector T-cell responses in non-lymphoid tissues: insights 
from in  vivo imaging. Immunol Cell Biol (2013) 91(4):290–6. doi:10.1038/
icb.2012.75 
58. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. 
In vivo imaging of cytotoxic T  cell infiltration and elimination of 
a solid tumor. J Exp Med (2007) 204(2):345–56. doi:10.1084/jem. 
20061890 
59. Breart B, Lemaitre F, Celli S, Bousso P. Two-photon imaging of intratumoral 
CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin 
Invest (2008) 118(4):1390–7. doi:10.1172/JCI34388 
60. Celli S, Albert ML, Bousso P. Visualizing the innate and adaptive immune 
responses underlying allograft rejection by two-photon microscopy. Nat Med 
(2011) 17(6):744–9. doi:10.1038/nm.2376 
61. Egen JG, Rothfuchs AG, Feng CG, Horwitz MA, Sher A, Germain RN. Intravital 
imaging reveals limited antigen presentation and T cell effector function in 
mycobacterial granulomas. Immunity (2011) 34(5):807–19. doi:10.1016/j. 
immuni.2011.03.022 
62. Dieckmann NM, Frazer GL, Asano Y, Stinchcombe JC, Griffiths GM. 
The cytotoxic T  lymphocyte immune synapse at a glance. J Cell Sci (2016) 
129(15):2881–6. doi:10.1242/jcs.186205 
63. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion 
of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflam-
mation. J Clin Invest (2002) 109(1):41–50. doi:10.1172/JCI0211638 
64. Bousso P, Moreau HD. Functional immunoimaging: the revolution continues. 
Nat Rev Immunol (2012) 12(12):858–64. doi:10.1038/nri3342 
65. Reiner T, Thurber G, Gaglia J, Vinegoni C, Liew CW, Upadhyay R, et  al. 
Accurate measurement of pancreatic islet beta-cell mass using a second- 
generation fluorescent exendin-4 analog. Proc Natl Acad Sci U S A (2011) 
108(31):12815–20. doi:10.1073/pnas.1109859108 
66. Chen C, Chmelova H, Cohrs CM, Chouinard JA, Jahn SR, Stertmann J, et al. 
Alterations in beta-cell calcium dynamics and efficacy outweigh islet mass 
adaptation in compensation of insulin resistance and prediabetes onset. 
Diabetes (2016) 65(9):2676–85. doi:10.2337/db15-1718 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Benson, Garcon, Recino, Ferdinand, Clatworthy, Waldmann, 
Brewer, Okkenhaug, Cooke, Garside and Wållberg. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) and the copyright owner are credited and that the original publi-
cation in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these terms.
